Cbdmd, INC

cbdMD has amended its Charlotte facility lease to reduce its footprint by 50% and extend the term through November 2031.

cbdMD, Inc. announced updated compensation for its independent directors, including restricted stock units and annual cash retainers.

cbdMD, Inc. shareholders approved a new equity compensation plan, a potential reverse stock split, and several dilutive share issuances at its 2026 Annual Meeting.

cbdMD, Inc. has acquired substantially all assets of Gaia Botanicals, LLC, including the Bluebird Botanicals brand, for common stock and an earnout, expanding its CBD product offerings.

cbdMD, Inc. announced it has regained full compliance with NYSE American continued listing standards, removing the '.BC' indicator.

cbdMD, Inc. announced a new three-year employment agreement for CEO and CFO T. Ronan Kennedy, alongside the approval of a 2025 Equity Compensation Plan reserving 891,316 shares.

cbdMD, Inc. reported a 12% decline in Q3 net sales but significantly improved stockholders' equity and NYSE American listing compliance through a preferred stock conversion and reverse stock split.

cbdMD, Inc. reports its Q2 2025 financial results, highlighting a focus on profitability, strategic initiatives, and addressing compliance with NYSE American continued listing standards.

cbdMD, Inc. reports its first quarter fiscal 2025 results, highlighting net income achievement and positive EBITDA, marking a turning point in the company's financial performance.

cbdMD, Inc. reported its Q3 2024 financial results, highlighting a focus on cost reduction and revenue growth initiatives despite a year-over-year decrease in net sales.

cbdMD, Inc. reported a net loss for the second quarter of 2024, while implementing cost-cutting measures and strategic shifts to improve profitability.

cbdMD, Inc. reported a decrease in net sales for the first quarter of fiscal year 2024, alongside a reduction in operating expenses as the company focuses on profitability and strategic initiatives.

cbdMD, Inc. filed an amended annual report to include executive compensation, corporate governance, and related party transaction details previously omitted from its 2025 10-K.

cbdMD, Inc. reports reduced operating losses and secures new capital through preferred stock and equity line, while facing significant regulatory challenges in the hemp-derived cannabinoid market.

cbdMD, Inc. filed an amendment to its annual report on Form 10-K to include information previously omitted regarding directors, executive officers, and executive compensation.

cbdMD, Inc. reports a reduced operating loss and improved adjusted EBITDA for fiscal year 2024, while navigating industry headwinds and focusing on strategic growth initiatives.

cbdMD, Inc. has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and corporate governance.

Director Jeffrey H. Porter was granted 1,572 restricted stock units as compensation for his service on the board of cbdMD, Inc.

Director Kevin Roe was granted 1,572 restricted stock units as compensation for his service on the board of cbdMD, Inc.

Director Sybil Nichole Swift was granted 1,572 restricted stock units as compensation for board services.

Director Bakari Sellers was granted 1,572 restricted stock units as compensation for board service at cbdMD, Inc.

Director Scott Stephen was granted 1,572 restricted stock units as compensation for his service on the board of cbdMD, Inc.

Director William F. Raines III was granted 1,572 restricted stock units as compensation for his service on the board of cbdMD, Inc.

cbdMD is asking shareholders to vote on proposals including a reverse stock split and the conversion of Series A Preferred Stock to common stock at the upcoming annual meeting to address NYSE American listing requirements and improve the company's financial position.

cbdMD, Inc. has filed a definitive proxy statement related to its upcoming shareholder meeting.

cbdMD, Inc. has filed an investor presentation with the SEC in preparation for its Annual Meeting of Shareholders on March 29, 2024.

cbdMD, Inc. registers up to 2,000,000 common shares for resale by selling shareholders, stemming from recent Series C Preferred Stock conversions, with no new proceeds for the company.

cbdMD, Inc. has entered into a $20 million equity line of credit agreement with C/M Capital Master Fund, LP to bolster working capital and general corporate purposes, while navigating significant dilution risks.

cbdMD, Inc. filed an S-1/A to register 1.7 million common shares for resale by Series B Preferred Stock holders, while detailing recent capital raises, reduced operating losses, and significant regulatory challenges.

cbdMD, Inc. filed an S-1 registration statement for the resale of 1.7 million common shares by selling shareholders who acquired Series B Convertible Preferred Stock.

cbdMD, Inc. has filed a registration statement for the potential resale of up to 5,138,890 shares of its common stock by selling shareholders, stemming from a recent private placement involving convertible notes.

cbdMD, Inc. has filed a registration statement for the potential resale of up to 5,138,890 shares of its common stock by selling shareholders, following a recent private placement involving convertible notes.

cbdMD, Inc. director Jeffrey Porter has reported beneficial ownership of 6.44% of the company's common stock after an automatic conversion of preferred shares and a subsequent one-for-8 reverse stock split.

Clark R. Crosnoe and affiliated entities have filed an amended Schedule 13G, reporting a collective beneficial ownership of 4.9% of cbdMD, INC.'s common shares.

Clark R. Crosnoe and associated entities have disclosed a combined 11.1% passive beneficial ownership stake in cbdMD, Inc. common shares, following recent corporate actions including a preferred stock conversion and a reverse stock split.